Efficacy Studies CROs

Global leader in providing preclinical and clinical laboratory services. Charles River offers early-stage discovery, safety assessment, and clinical support services to pharmaceutical and biotech companies worldwide.

Specialty CRO focused on translational oncology services. Champions provides patient-derived xenograft (PDX) tumor models, ex vivo tumor platforms, and oncology pharmacology studies.

Contract research organization providing drug discovery and development services including preclinical safety assessment, bioanalytical services, and research animal models.

Preclinical CRO specializing in in vitro pharmacology, receptor binding, enzyme inhibition assays, and ADME screening for drug discovery programs.

Research models and services provider offering genetically defined laboratory animals, contract research services, and scientific consulting for preclinical drug development.

Specialty preclinical CRO focused on Asia-Pacific markets, providing preclinical safety assessment, pharmacology, and bioanalytical services for small molecule and biologic programs.

Japanese preclinical CRO providing GLP safety assessment, pharmacokinetics, and toxicology studies with specialized NHP and inhalation toxicology capabilities from facilities in Japan and the US.

Chinese integrated drug discovery and development CRO providing medicinal chemistry, ADME/PK, pharmacology, toxicology, and CMC services from Shanghai operations.

Translational oncology and metabolic disease CRO providing tumor models (PDX, syngeneic, humanized), oncology pharmacology, and biomarker services for drug discovery.

World-leading ophthalmology-specialized CRO conducting preclinical and clinical research from ocular surface to posterior segment, with 70+ ocular drugs and devices brought to market.

Denmark-based GLP preclinical CRO offering safety pharmacology, general toxicology, reproductive toxicology, and ADME studies, known for rodent and non-rodent capabilities including minipig models.

French preclinical CRO based in Lyon evaluating efficacy and safety of new compounds including drugs, biologics, and medical devices across innovative in-vitro and in-vivo models.

Large preclinical CRO in Michigan acquired by Charles River Laboratories, providing GLP toxicology, safety pharmacology, and ADME studies in purpose-built facilities spanning over 800,000 sq ft.

US subsidiary of Shin Nippon Biomedical Laboratories specializing in GLP preclinical safety assessment including general toxicology, reproductive toxicology, and inhalation studies with NHP and rodent capabilities.

Independent nonprofit applied science and technology organization providing preclinical research, inhalation toxicology, bioanalytical services, and pharmaceutical development support.

Preclinical CRO in Pennsylvania providing GLP and non-GLP toxicology, safety pharmacology, and pathology services with a focus on small and large molecule therapeutics.

Nonprofit research organization providing drug discovery, preclinical development, and analytical services with deep expertise in oncology and infectious disease including BSL-3 capabilities.

Chinese preclinical CRO providing GLP-compliant safety evaluation, pharmacokinetics, efficacy studies, and drug metabolism studies with comprehensive NHP and rodent capabilities.

GLP-compliant preclinical CRO specializing in toxicology, pathology, and ADME studies for pharmaceutical, biotech, and agrochemical clients with full necropsy and histopathology capabilities.

Preclinical oncology CRO using patient-derived tumor models and TumorGraft technology for in vivo efficacy studies, providing translational research services for oncology drug development.

South Korean pharmaceutical research institute providing preclinical safety assessment, ADME/PK studies, and efficacy testing from GLP-certified facilities in Seoul.

Nordic preclinical CRO providing in vivo pharmacology, efficacy, and safety studies with expertise in metabolic disease, inflammation, and fibrosis models using rodent species.

Not-for-profit preclinical CRO with ABSL-3 capabilities and expertise in inhalation toxicology, pulmonary delivery, and infectious disease models from 100+ acre campus.

Oncology-focused CRO founded on the Mayo Clinic campus offering preclinical-to-clinical oncology development with PDX models, flow cytometry, and Phase I/II trial management.

World's largest nonprofit R&D organization offering GLP-compliant preclinical safety, toxicology, inhalation studies, and bioanalytical services including BSL-3 biocontainment capabilities.

Independent not-for-profit preclinical CRO offering full IND-enabling GLP toxicology programs, inhalation toxicology, and immunogenicity testing from the Illinois Institute of Technology campus.

Specialty CRO providing GLP-compliant anatomic pathology, histotechnology, and immunohistochemistry services for pharma, biotech, and government preclinical research programs.

German preclinical oncology CRO providing patient-derived xenograft models, ex vivo tumor assays, and in vivo efficacy studies for oncology drug development programs.

European CRO providing preclinical contract research services including in vivo pharmacology, toxicology, and bioanalytical testing from GLP-certified European facilities.

Japan's pioneering CRO founded in 1957 offering non-clinical safety evaluation including NHP studies, clinical Phase I-IV development, and a proprietary nasal drug delivery platform.

Kobe-based Japanese CRO and research institute specializing in preclinical safety assessment, pharmacology and drug metabolism studies with GLP-accredited facilities.

LabCorp Drug Development preclinical and toxicology centre in Madison, Wisconsin, providing GLP-compliant general and genetic toxicology, safety pharmacology, and reproductive toxicology studies.

Exton, Pennsylvania-based preclinical CRO providing in vivo PK/PD studies, ADME services, and GLP bioanalytical testing for small-molecule and biologic drug candidates.

Full-continuum preclinical CRO providing integrated in vitro and in vivo services including efficacy, toxicity, biodistribution, and product release studies in small and large animals.

Preclinical CRO specialising in immunotoxicology and immune safety assessment, offering in vivo and in vitro studies for pharma, biotech, and government clients.

AI-enabled precision oncology CRO using patient-derived xenograft models and ex vivo pharmacology to generate predictive therapeutic response data for drug developers.

Indian CRO affiliated with Dabur offering preclinical drug discovery, IND-enabling studies, and non-clinical research services from facilities near Delhi.

Chinese CRO and CDMO offering integrated preclinical biology, in-vitro pharmacology, and early drug discovery services for domestic and multinational pharma clients.

Kentucky-based preclinical CRO specialising in oncology efficacy studies using proprietary humanised rodent models and patient-derived xenografts for immuno-oncology drug development.

Shanghai-based preclinical CRO providing in vivo pharmacology, toxicology, DMPK, and bioanalytical services with specialized PDX platforms for oncology drug development.

Singapore-based specialty CRO providing preclinical pharmacology, toxicology, and early clinical development services with particular expertise in biologics and biosimilar characterization.

Thai royal research institute conducting preclinical and clinical research in oncology, environmental toxicology, and natural products with GLP-certified laboratory facilities.

Israeli biotech CRO specializing in preclinical efficacy models for wound healing, dermatology, and fibrosis, providing contract research services with proprietary animal models and histopathology analysis.

Preclinical CRO specializing in CNS drug discovery using proprietary AI-powered behavioral phenotyping platforms for neurological and psychiatric disorders.

Preclinical neuroscience CRO spun out of GlaxoSmithKline in 2010, specializing in in vivo CNS pharmacology models for psychedelic compound and neurodegeneration research.

European preclinical CRO in Dijon, France, specializing in oncology, inflammation, and infectious disease drug discovery including targeted radiotherapy programs.

Fully independent European preclinical CRO in Madrid delivering GLP-certified toxicology and safety studies aligned with EMA and FDA regulatory requirements.

Barcelona-based preclinical CRO pioneering zebrafish-based platforms for efficacy testing, safety pharmacology, and toxicity assessment of pharmaceutical and chemical compounds.

Global preclinical and drug discovery CRO offering the world's largest catalog of human fresh tissue assays for efficacy, ADME, and safety testing in GLP-accredited labs across the US, UK, and Japan.

GLP-compliant preclinical CRO in Austin, Texas, offering 100+ validated xenograft efficacy models, IND-enabling toxicology, and RNAi therapeutic development services.

Independent GLP preclinical CRO and testing laboratory in Sugar Land, Texas, covering mammalian toxicology, aquatic, environmental, and animal health studies since 1975.

Precision oncology CRO using patient-derived orthotopic xenograft models and predictive AI to guide drug selection and oncology development decisions.

Specialist preclinical ophthalmology CRO with AAALAC-accredited labs in Oklahoma City and Ann Arbor, providing pharmacology, PK/tox, bioanalysis, and formulation services for ocular drug development.

Specialty preclinical CRO focused on non-GLP ophthalmic and oncology efficacy studies, providing in vivo animal model services for ocular disease and solid tumor drug development.